AtriCure Inc. (ATRC)
NASDAQ: ATRCHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATRC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.82B
- P/E (TTM)
- 178.68
- Forward P/E
- 122.12
- EPS (TTM)
- $0.31
- Dividend yield
- None
- 52-week range
- 25.36 – 66.02
- Day range
- 54.03 – 56.14
- Volume / Avg
- 813.08K / 1.04M
- Beta
- —
- Shares outstanding
- 50.92M
52-week range
ATRC stock today
AtriCure (ATRC) closed at $55.39 on Nov 20, up 2.37% (+$1.28), versus the S&P 500's 3.70% decline. At this level, ATRC sits in the middle of its 52-week range of $25.36 to $66.02: 16.1% below the high, set on Nov 4, 2026 and 118.4% above the low. ATRC is up 40.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 53.1%.
At 178.7x trailing earnings, AtriCure trades above the peer-group median of 26.8x. Its forward P/E of 122.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About AtriCure
Company profileAtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael H. Carrel
- Headquarters
- Mason, OH
- Employees
- 1,350
- IPO year
- 2005
- Website
- atricure.com
Financial highlights
Full financialsIn fiscal 2025, AtriCure generated $534.5 million in revenue, up 14.9% from fiscal 2024, its 5th consecutive year of revenue growth. AtriCure reported a net loss of $11.4 million, compared with a loss of $44.7 million a year earlier. Gross margin was 75.0% (up from 74.7%) and operating margin -1.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $534.53M | $465.31M | $399.25M | $330.38M | $274.33M |
| Growth | +14.88% | +16.55% | +20.84% | +20.43% | +32.83% |
| Net income | $-11.45M | $-44.70M | $-30.44M | $-46.47M | $50.20M |
| EPS (diluted) | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$64.89+17.15%
- Strong buy 3
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.01 vs $0.01
- Surprise
- -200.00%
ATRC news
All ATRC news- AtriCure projects 2026 adjusted EBITDA of $91M-$94M as it targets BoxX-NoAF enrollment completion by year-endSeeking Alpha
- AtriCure Reports Third Quarter 2026 Financial ResultsBusiness Wire
- AtriCure to Announce Third Quarter 2026 Financial ResultsBusiness Wire
- Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMNNasdaqATRC, ILMN, MRNA, TKNO
- Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTHNasdaqATRC, BLSM, FTH, PHVS
AtriCure peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRTCiRhythm Holdings Inc. | 94.72 | +0.51% | $3.18B | vs ATRC |
| PLSEPulse Biosciences Inc | 45.55 | +2.57% | $3.35B | vs ATRC |
| UFPTUFP Technologies Inc. | 290.85 | -2.70% | $2.25B | vs ATRC |
| NVSTEnvista Holdings Corporation | 22.91 | -1.55% | $3.67B | vs ATRC |
| LMATLeMaitre Vascular Inc. | 73.61 | -1.67% | $1.68B | vs ATRC |
| XRAYDENTSPLY SIRONA Inc. | 8.29 | -2.36% | $1.65B | vs ATRC |
| INSPInspire Medical Systems Inc. | 55.10 | -2.10% | $1.60B | vs ATRC |
| HTFLHeartflow Inc. | 46.69 | +4.62% | $4.10B | vs ATRC |
Indexes, lists and sector
AtriCure stock FAQ
What is AtriCure's stock price today?
ATRC last traded at $55.39 as of Nov 20, 4:00 PM EST, up 2.37% on the day. Prices are delayed at least 15 minutes.
What is ATRC's P/E ratio?
ATRC trades at a trailing P/E ratio of 178.68 and a forward P/E of 122.12, compared with a median of 26.8 for its closest peers.
Who is AtriCure's CEO?
Mr. Michael H. Carrel is the chief executive officer of AtriCure Inc., which has about 1,350 employees.
What is the ATRC 52-week high?
The 52-week high for ATRC is $66.02 and the 52-week low is $25.36. The stock is currently 16.1% below its high.